TLSI Insider Trading

Insider Ownership Percentage: 32.80%
Insider Buying (Last 12 Months): $345,189.24
Insider Selling (Last 12 Months): $1,443.66

TriSalus Life Sciences Insider Trading History Chart

This chart shows the insider buying and selling history at TriSalus Life Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$200k-$100k$0$100k$200kTotal Insider BuyingTotal Insider Selling

TriSalus Life Sciences Share Price & Price History

Current Price: $4.99
Price Change: Price Increase of +0.125 (2.57%)
As of 01/22/2025 04:22 PM ET

This chart shows the closing price history over time for TLSI up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MarAprMayJunJulAugSepOctNovDecJan$4.86Closing price on 01/21/25:

SEC Filings (Institutional Ownership Changes) for TriSalus Life Sciences (NASDAQ:TLSI)

2.58% of TriSalus Life Sciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at TLSI by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
202220232024$798kbought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4-$1M$0$1MTotal InflowsTotal Outflows
TriSalus Life Sciences logo
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
Read More on TriSalus Life Sciences

Today's Range

Now: $4.99
Low: $4.95
High: $5.15

50 Day Range

MA: $4.45
Low: $3.60
High: $5.16

52 Week Range

Now: $4.99
Low: $3.50
High: $10.42

Volume

9,292 shs

Average Volume

18,492 shs

Market Capitalization

$151.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.51

Who are the company insiders with the largest holdings of TriSalus Life Sciences?

TriSalus Life Sciences' top insider shareholders include:
  1. Equity Ab Frankenius (Major Shareholder)
  2. Mary T Szela (CEO)
  3. George Kelly Martin (Director)
  4. Bryan F Cox (Insider)
  5. Mats Wahlstrom (Director)
Learn More about top insider investors at TriSalus Life Sciences.